U.S. patent application number 11/524315 was filed with the patent office on 2007-06-14 for double-stranded rna oligonucleotides which inhibit tyrosinase expression.
This patent application is currently assigned to L'OREAL. Invention is credited to Christine Collin-Djangone, Jean-Thierry Simonnet.
Application Number | 20070134188 11/524315 |
Document ID | / |
Family ID | 36716947 |
Filed Date | 2007-06-14 |
United States Patent
Application |
20070134188 |
Kind Code |
A1 |
Collin-Djangone; Christine ;
et al. |
June 14, 2007 |
Double-stranded RNA oligonucleotides which inhibit tyrosinase
expression
Abstract
Novel double-stranded RNA oligonucleotides are useful for
decreasing tyrosinase expression, have cosmetic and/or
pharmaceutical applications, for example are useful skin
depigmenting or anti-browning agents, and can be associated with
cationic particles less than or equal to 1 .mu.m in size, having a
zeta potential of from 10 to 80 mV.
Inventors: |
Collin-Djangone; Christine;
(Amblainville, FR) ; Simonnet; Jean-Thierry;
(Cachan, FR) |
Correspondence
Address: |
BUCHANAN, INGERSOLL & ROONEY PC
POST OFFICE BOX 1404
ALEXANDRIA
VA
22313-1404
US
|
Assignee: |
L'OREAL
PARIS
FR
|
Family ID: |
36716947 |
Appl. No.: |
11/524315 |
Filed: |
September 21, 2006 |
Current U.S.
Class: |
424/70.13 ;
424/489; 514/44A |
Current CPC
Class: |
C12N 15/1137 20130101;
C12Y 114/18001 20130101; A61K 2800/782 20130101; C12N 2310/14
20130101; A61K 8/606 20130101; A61P 17/00 20180101; A61P 43/00
20180101; A61Q 19/02 20130101; A61P 17/16 20180101 |
Class at
Publication: |
424/070.13 ;
424/489; 514/044 |
International
Class: |
A61K 48/00 20060101
A61K048/00; A61K 8/73 20060101 A61K008/73; A61K 9/14 20060101
A61K009/14 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 21, 2005 |
FR |
05/09658 |
Claims
1. A cosmetic/pharmaceutical composition comprising at least one
double-stranded RNA oligonucleotide of a sequence selected from the
group consisting of SEQ ID NOS. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47 and 48 together with a population of cationic particulates
less than or equal to 1 .mu.m in size, and having a zeta potential
ranging from 10 to 80 mV.
2. The cosmetic/pharmaceutical composition as defined by claim 1,
said at least one RNA oligonucleotide being -o-methylated at the
2'-position thereof.
3. The cosmetic/pharmaceutical composition as defined by claim 1,
comprising less than or equal to 100 .mu.M of said at least one RNA
oligonucleotide.
4. The cosmetic/pharmaceutical composition as defined by claim 1,
said population of cationic particulates comprising surfactant
micelles, block polymer micelles, liposomes of nonionic and
cationic surfactants, niosomes, oleosomes, particles of
nanoemulsions, nanocapsules, organic particles or inorganic
particles.
5. The cosmetic/pharmaceutical composition as defined by claim 1,
said cationic particulates being less than or equal to 500 nm in
size.
6. The cosmetic/pharmaceutical composition as defined by claim 1,
said cationic particulates being less than or equal to 300 nm in
size.
7. The cosmetic/pharmaceutical composition as defined by claim 1,
said cationic particulates comprising micelles of nonionic
amphiphilic surfactants and of cationic surfactants.
8. The cosmetic/pharmaceutical composition as defined by claim 4,
comprising block polymer micelles selected from the group
consisting of micelles of a cationic amphiphilic block polymer,
micelles of a nonionic amphiphilic block polymer and of a cationic
amphiliphic block polymer and micelles of a nonionic amphiphilic
block polymer and of a cationic surfactant.
9. A regime or regimen for inhibiting tyrosinase expression,
comprising administering to an individual in need of such
treatment, a thus effective amount of at least one double-stranded
RNA oligonucleotide of a sequence selected from the group
consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
and 48.
10. A regime or regimen for inhibiting tyrosinase expression,
comprising administering to an individual in need of such
treatment, a thus effective amount of at least one double-stranded
RNA oligonucleotide of a sequence selected from the group
consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
and 48 together with a population of cationic particulates less
than or equal to 1 .mu.m in size, and having a zeta potential
ranging from 10 to 80 mV.
11. A regime or regimen for the bleaching and/or anti-browning of
the skin, comprising topically applying onto the skin of an
individual in need of such treatment, a thus effective amount of at
least one double-stranded RNA oligonucleotide of a sequence
selected from the group consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47 and 48.
12. A regime or regimen for the bleaching and/or anti-browning of
the skin, comprising topically applying onto the skin of an
individual in need of such treatment, a thus effective amount of at
least one double-stranded RNA oligonucleotide of a sequence
selected from the group consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47 and 48 together with a population of
cationic particulates less than or equal to 1 .mu.m in size, and
having a zeta potential ranging from 10 to 80 mV.
13. A regime or regimen for preventing the formation of and/or
eliminating pigmentation marks, and/or senescence marks, and/or for
lightening and/or bleaching browned skin and/or rendering the color
of browned skin uniform, comprising topically applying onto the
skin of an individual in need of such treatment, a thus effective
amount of at least one double-stranded RNA oligonucleotide of a
sequence selected from the group consisting of SEQ ID NOS. 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47 and 48.
14. A regime or regimen for preventing the formation of and/or
eliminating pigmentation marks, and/or senescence marks, and/or for
lightening and/or bleaching browned skin and/or rendering the color
of browned skin uniform, comprising topically applying onto the
skin of an individual in need of such treatment, a thus effective
amount of at least one double-stranded RNA oligonucleotide of a
sequence selected from the group consisting of SEQ ID NOS. 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47 and 48 together with a population of
cationic particulates less than or equal to 1 .mu.m in size, and
having a zeta potential ranging from 10 to 80 mV.
15. A regime or regimen for depigmenting the skin, comprising
topically applying onto the skin of an individual in need of such
treatment, a thus effective amount of at least one double-stranded
RNA oligonucleotide of a sequence selected from the group
consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
and 48.
16. A regime or regimen for depigmenting the skin, comprising
topically applying onto the skin of an individual in need of such
treatment, a thus effective amount of at least one double-stranded
RNA oligonucleotide of a sequence selected from the group
consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
and 48 together with a population of cationic particulates less
than or equal to 1 .mu.m in size, and having a zeta potential
ranging from 10 to 80 mV.
17. A regime or regimen for treating idiopathic melasmas,
hyperpigmentations associated with pregnancy or with
oestro-progestin contraception, accidental hyperpigmentations,
hyperpigmentations due to leukoderma, and/or vitiligo, comprising
topically applying onto the skin of an individual in need of such
treatment, a thus effective amount of at least one double-stranded
RNA oligonucleotide of a sequence selected from the group
consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
and 48.
18. A regime or regimen for treating idiopathic melasmas,
hyperpigmentations associated with pregnancy or with
oestro-progestin contraception, accidental hyperpigmentations,
hyperpigmentations due to leukoderma, and/or vitiligo, comprising
topically applying onto the skin of an individual in need of such
treatment, a thus effective amount of at least one double-stranded
RNA oligonucleotide of a sequence selected from the group
consisting of SEQ ID NOS. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
and 48 together with a population of cationic particulates less
than or equal to 1 .mu.m in size, and having a zeta potential
ranging from 10 to 80 mV.
19. The cosmetic/pharmaceutical composition as defined by claim 1,
formulated into a topically applicable medium therefor, said at
least one RNA oligonucleotide comprising less than or equal to 100
.mu.M thereof.
20. The regime or regimen as defined by claim 9, preceded by a
pretreatment of the skin comprising a stripping, a chemical peel, a
mechanical dermabrasion, topical application of one or more
solvents having a defatting effect, and/or cleansing the skin with
a detergent foaming product.
21. The regime or regimen as defined by claim 10, preceded by a
pretreatment of the skin comprising a stripping, a chemical peel, a
mechanical dermabrasion, topical application of one or more
solvents having a defatting effect, and/or cleansing the skin with
a detergent foaming product.
22. The regime or regimen as defined by claim 9, followed by an
occlusive post-treatment.
23. The regime or regimen as defined by claim 10, followed by an
occlusive post-treatment.
24. The regime or regimen as defined by claim 9, administered
without inducing an interferon response.
25. The regime or regimen as defined by claim 10, administered
without inducing an interferon response.
26. A population of cationic particulates less than or equal to 1
.mu.M in size, having a zeta potential ranging from 10 to 80 mV,
and having at least one double-stranded RNA oligonucleotide of a
sequence selected from the group consisting of SEQ ID NOS. 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47 and 48 adhered to the face surfaces
thereof.
27. The cosmetic/pharmaceutical composition as defined by claim 1,
formulated as a solution, gel, lotion, serum, milk, emulsion,
dispersion, suspension, cream, microcapsules, microparticles, or
vesicular dispersion.
Description
CROSS-REFERENCE TO PRIORITY APPLICATION
[0001] This application claims priority under 35 U.S.C. .sctn. 119
of FR 05/09658, filed Sep. 21, 2005, hereby expressly incorporated
by reference and assigned to the assignee hereof.
BACKGROUND OF THE INVENTION
[0002] 1. Technical Field of the Invention
[0003] The present invention relates to novel double-stranded RNA
oligonucleotides for decreasing tyrosinase expression, to the use
thereof for cosmetic and/or pharmaceutical purposes and also to the
association thereof with cationic particles less than or equal to 1
.mu.m in size, with a zeta potential ranging from 10 to 80 mV.
[0004] 2. Description of Background and/or Related and/or Prior
Art
[0005] Tyrosinase (monophenol dihydroxylphenylalanine: oxygen
oxidoreductase EC 1.14.18.1) is the essential enzyme involved in
the mechanism of skin pigmentation. It catalyzes in particular the
reaction for conversion of tyrosine to Dopa
(dihydroxyphenylalanine) by virtue of its hydroxylase activity and
the reaction for conversion of Dopa to dopaquinone by virtue of its
oxidase activity. The tyrosinase acts only when it is in the
maturation state under the action of certain biological
factors.
[0006] This enzyme can also be advantageous in the treatment of
pathologies such as melanoma (Riley et al., J. Immunother., 2001,
21, 212-220) or Vogt-Koyanagi-Harada disease (Read et al., Curr.
Opin. Ophthalmol., 2000, 11, 437-442).
[0007] The mechanism of formation of skin pigmentation, i.e., the
formation of melanin, is particularly complex and involves
schematically the following main steps: [0008]
Tyrosine.fwdarw.Dopa.fwdarw.Dopaquinone.fwdarw.Dopachrome.fwdarw.Melanin
[0009] Thus, the pigmentation of human skin results from the
synthesis of melanin by dendritic cells, melanocytes. The latter
contain organelles called melanosomes, which are the site of
melanin biosynthesis. It is the melanosomes which, after migration
along the dendrites, are transferred from the melanocytes to the
keratinocytes. The keratinocytes are then transported to the
surface of the skin during the epidermal differentiation process
(Gilchrest B A, Park H Y, Eller M S, Yaar M, Mechanisms of
ultraviolet light-induced pigmentation, Photochem Photobiol., 1996;
63: 1-10; Hearing V J, Tsukamodo K, Enzymatic control of
pigmentation in mammals, FASEB J., 1991; 5: 2902-2909).
[0010] Among melanogenesis enzymes, tyrosinase is a key enzyme
which catalyses the first two steps of melanin synthesis.
Homozygous mutations for tyrosinase cause oculocutaneous albinism
type I characterized by a complete absence of melanin synthesis
(Toyofuku K, Wada I, Spritz R A, Hearing V J, The molecular basis
of oculocutaneous albinism type 1 (OCA1): sorting failure and
degradation of mutant tyrosinases results in a lack of
pigmentation, Biochem J., 2001; 355: 259-269).
[0011] Since hyperpigmentation disorders result from an increase in
melanin production, the development of novel therapeutic
approaches, the rationale of which is based on the inhibition of
tyrosinase activity, is found to be important.
[0012] Most of the skin-lightening compounds already known are
phenols/catechols. These compounds inhibit tyrosinase but most of
these compounds are cytotoxic with respect to melanocytes, which
could cause permanent depigmentation of the skin.
[0013] It therefore appears to be advantageous, for an application
in humans, to have novel tyrosinase-inhibiting compounds that are
both highly effective and exhibit good tolerance.
[0014] Of late, the use of double-stranded RNA, dsRNA,
oligonucleotides, and more particularly of siRNA oligonucleotides
(of 12 to 40 nucleotides), would make it possible to obtain a
specific activity in the cosmetic field, such as skin care or hair
care, but also in the dermatological and pharmaceutical fields.
[0015] However, the use of siRNAs in vivo is known to present
various difficulties.
[0016] Besides the problem of the penetration of these siRNAs in
order to reach the target cells when they are applied topically,
due in particular to the difficulty in crossing the stratum
corneum, experience has shown that the administration of siRNAs
could bring about the triggering of an interferon response reported
by numerous publications (Sledz C A et al., Activation of the
interferon system by short-interfering RNA, Nat Cell Biol., 2003;
9:834-9. Katalin Kariko et al., Small Interfering RNAs Mediate
Sequence-independent Gene Suppression and Induce Immune Activation
by Signaling through Toll-Like Receptor 31, J. Immunol., 2004; 172:
6545-6549. Judge A D et al., Sequence-dependent stimulation of the
mammalian innate immune response by synthetic siRNA, Nat.
Biotechnol., 2005; 23:457-62) and also the induction or the
inhibition of the expression of genes not targeted by the siRNA
(Jackson et al., Expression profiling reveals off-target gene
regulation by RNAi, Nat. Biotechnol., 2003; 21:635-7), these two
phenomena are highly undesirable.
[0017] Published U.S. Application No. 2004/0215006 describes
double-stranded and anti-sense single-stranded RNA oligonucleotides
which are active against tyrosinase; the examples relate only to
anti-sense single-stranded RNA oligonucleotides. In particular, it
is not demonstrated whether the siRNAs homologous to these
anti-sense RNAs are effective.
[0018] Some authors have emphasized that double-stranded RNA
oligonucleotides, such as siRNAs, and anti-sense single-stranded
RNA oligonucleotides have different targets and that the activity
of an anti-sense RNA cannot be extrapolated to the siRNA of the
same sequence (Xu et al., Effective small interfering RNAs and
phosphorothioate anti-sense DNAs have different preferences for
target sites in the luciferase mRNAs, BBRC 2003; 306:712-717).
[0019] Moreover, in said 2004/0215006, the concentrations of siRNA
proposed are from 50 and 200 nM. As indicated above, Jackson et
al., have described a strong positive and negative regulation of
genes not targeted by the siRNAs used at concentrations of 100
nM.
[0020] Similarly, in WO 2005/060536, which describes siRNAs that
specifically inhibit tyrosinase, the concentration ranges proposed
are very wide and can result in compositions comprising a very
large amount of siRNAs for which a positive and negative regulation
of genes not targeted by the siRNAs may be observed.
[0021] In the context of a cosmetic or therapeutic use, this
regulation of non-targeted genes is not acceptable, in particular
due to its unpredictable nature.
SUMMARY OF THE INVENTION
[0022] Novel siRNAs have now been developed that specifically
inhibit tyrosinase expression from which siRNAs have been selected
which exhibit an activity such that the siRNAs can be used at a
dose of less than or equal to 1 nM.
[0023] In addition to solving the problems related to the induction
of nonspecific genes, it has now been verified that these sequences
of siRNAs do not induce an interferon response.
[0024] For this, the expression was measured of the OAS-1 and
IFIT-1 (interferon-inducible tetratricopeptide repeat domain) genes
known to be induced by interferon (Stefan F. Wieland et al.,
Searching for Interferon-Induced Genes that inhibit Hepatitis B
Virus Replication in Transgenic Mouse Hepatocytes, J. of Virology
2003, 77:1227-1236) according to the protocol described in the
manual of the "BLOCK-iT.TM. RNAi Stress Response Control Kit
(Human) for monitoring interferon-mediated stress response to
double-stranded RNA in human cells" marketed by Invitrogen.
[0025] Furthermore, the association of these tyrosinase-specific
siRNAs with cationic particles less than or equal to 1 .mu.m in
size, with a zeta potential of 10 to 80 mV, makes it possible to
very significantly improve their penetration into the target cells
of a three-dimensional model such as the skin. Once penetrated, the
tyrosinase-specific siRNA becomes active.
[0026] The penetration can be evaluated by means of a fluorescent
label attached to the siRNA and its activity can be evaluated by
quantifying the targeted messenger by quantitative PCR or by
assaying the protein corresponding to the targeted messenger.
[0027] The cationic particles of the invention may be surfactant
micelles, micelles of block or non-block polymers, cationic
liposomes and niosomes, cationic oleosomes, cationic nanoemulsions,
and also cationic organic or inorganic particles and
nanocapsules.
[0028] Thus, the present invention features a double-stranded RNA
oligonucleotide (also called dsRNA or siRNA) selected from among
the oligonucleotides of sequence SEQ ID NOS. 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47 and 48, optionally modified.
[0029] The use of dsRNA and, more particularly, of siRNA (for short
interfering RNA) makes it possible to obtain an activity of
specific inhibition of the synthesis of a target protein by
degradation of the mRNA encoding the protein. The degradation of
the target mRNA is obtained through the activation of the RISC
complex (RNA Induced Silencing Complex) which has its effect
through the binding of the anti-sense strand of the dsRNA to the
mRNA (see Tuschl T. Chem. Biochem., 2001; 2:239-245; Nykanen A
& al, Cell 2001; 107:309-321; Dorsett Y. and Tuschl T. Nat Rev
Drug Discov., 2004; 3:318-329; Downward J. BMJ. 2004;
328:1245-1248; Shanker P. et al., JAMA 2005; 293:1367-1373).
[0030] The molecular mechanism implemented involves double-stranded
RNA fragments consisting of 12 to 40 nucleotides, preferably of 23
to 27 nucleotides.
[0031] These double-stranded RNA oligonucleotides can preferably be
composed of a homologous sense strand and of an anti-sense strand
complementary to the sequence of the mRNA of human tyrosinase
(GenBank accession number NM.sub.--000372). The double-stranded RNA
oligonucleotide has blunt ends or unpaired ends of 2 to 6
nucleotides.
[0032] The double-stranded RNA oligonucleotides can be synthesized
according to numerous manual or automatic, in vivo or in vitro
synthesis methods.
[0033] The in vitro synthesis methods may be chemical or enzymatic,
for example using an RNA polymerase (by way of example, T3, T7 or
SP6) which will carry out the transcription of a selected DNA (or
cDNA) sequence model.
DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED
EMBODIMENTS OF THE INVENTION
[0034] Numerous methods for the in vivo synthesis of
double-stranded RNA are described in the literature; they can be
carried out in various bacterial cell types or cell types from
higher organisms (Sambrook et al., Molecular Cloning, A Laboratory
Manual, Second Edition (1989), DNA cloning, volume I and II, D. N.
Glover (ed. 1985), Oligonucleotide Synthesis, M. J. Gaits (ed.
1984), Nucleic Acid Hybridation, B. D. Hames and S. J. Higgins (ed.
1984), Transcription and Translation B. D. Hames and S. J. Higgins
(ed. 1984), Animal Cell Culture, R. I. Freshney (ed. 1986),
Immobilized Cells and Enzymes, IRL Press (1986), B. Pertal, A
Practical Guide to Molecular Cloning (1984), Gene Transfer Vectors
for Mammalian Cells, J. H. Miller and M. P. Calos, Cold Spring
Harbor Laboratory (ed. 1987), Methods in Enzymology, vol. 154, Wu
and Grossman, and 155, Wu, Mayer and Walker (1987), Immunochemical
Methods in Cell and Molecular Biology, Academic Press, London,
Scopes (1987), Protein Purification: Principle and Practice, 2nd
ed., Springer-Verlag, N.-Y. and Handbook of Experimental
Immunology, vol. I-IV, C. D. Weir and C. C. Blackwell (1986)).
Reference may also be made to the synthesis methods described in WO
01/36646, WO 01/75164 and U.S. Patent Published Application No.
2003/0088087.
[0035] Preferably, the double-stranded RNA oligonucleotides
according to the invention are modified through the addition of an
-O-methyl group in the 2'-position.
[0036] The double-stranded RNA oligonucleotides can be subjected to
various modifications, they can in particular be modified as
described in Published U.S. Application No. 2004/014956.
[0037] Advantageously, the modifications will result in
double-stranded RNA oligonucleotides which are more stable, and,
more preferably, double-stranded RNA oligonucleotides which have
been rendered furtive with respect to the interferon response; this
property is essential for use in vivo. The double-stranded RNA
oligonucleotides may also have a sense sequence modified in such a
way that it cannot be incorporated into the RISC and therefore
cannot induce side effects.
[0038] Preferably, the double-stranded RNA oligonucleotides of SEQ
ID NOS. 1, 2, 4, 13, 16, 35, 37, 40 and 42, having a tyrosinase
mRNA degradation efficiency of greater than 50% at 0.016 nM,
measured according to the protocol of Example 2 hereinafter, will
be used.
[0039] The subject of the present invention also relates to a
composition comprising at least one double-stranded RNA
oligonucleotide selected from among the oligonucleotides of
sequence SEQ ID NOS. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and
48.
[0040] In this composition, the double-stranded RNA oligonucleotide
is present at a concentration of less than or equal to 100 .mu.M,
preferably less than or equal to 10 .mu.M, and more preferably less
than or equal to 1 .mu.M.
[0041] The compositions according to the invention are preferably
suitable for topical administration to the surface of the body,
i.e., the skin, the integuments, the mucous membranes and the
eyes.
[0042] In a preferred embodiment of the present invention, the
double-stranded RNA oligonucleotides are associated with a cationic
particle less than or equal to 1 .mu.m in size, with a zeta
potential of from 10 to 80 mV.
[0043] In this embodiment, the double-stranded RNA oligonucleotides
will adhere to the surface of the particle, the latter serving as a
carrier to cause it to penetrate into the structures of the skin
and into the target cells of the skin, of the mucous membranes or
else of the eyes for cosmetic, dermatological and/or ophthalmic
applications.
[0044] The cationic particles according to the invention are
particles that are less than or equal to 1 .mu.m, preferably less
than or equal to 500 nm, more preferably less than or equal to 300
nm, in size, it being possible to measure said size with, for
example, a laser particle sizer type BI90 plus from the company
Brookhaven, and that have a zeta potential of from 10 to 80 mV
which can be measured with a zetameter type DELSA 440 from the
company Coultronics.
[0045] The cationic particle can be selected from surfactant
micelles, in particular micelles of nonionic amphiphilic
surfactants and of cationic surfactants, block polymer micelles, in
particular micelles of a cationic amphiphilic block polymer,
micelles of a nonionic amphiphilic block polymer and of a cationic
amphiphilic block polymer and micelles of a nonionic amphiphilic
block polymer and of a cationic surfactant, liposomes of nonionic
and cationic surfactants, niosomes, oleosomes, particles of
nanoemulsions, nanocapsules, organic particles or inorganic
particles.
[0046] Listed below, and in a non-exhaustive manner, are cationic
particles which can be used according to the invention.
[0047] Surfactant Micelles:
[0048] To recall, micelles are aggregates that are spontaneously
formed by amphiphilic molecules when they are solubilized in water
or oil, beyond a certain concentration referred to as critical: the
CMC.
[0049] The micelles which can be used in the context of the
invention include at least one cationic surfactant. This cationic
surfactant can be associated with one or more nonionic amphiphilic
surfactants.
[0050] Those skilled in the art will advantageously select the
nonionic and cationic surfactants from McCutcheons 1998
"emulsifiers and detergents" and from the subsequent editions.
[0051] By way of non-limiting examples, the cationic surfactants
which can be used in the context of the invention are listed
hereinafter.
[0052] Without this being limiting, the nonionic surfactants which
can be used are: alkyl and polyalkyl (C6 to C30, saturated or
unsaturated, branched or unbranched) esters or ethers of PEO, of
glycerol and of polyglycerol, of sorbitan which may or may not be
oxyethylenated, of sucrose, of glucose which may or may not be
oxyethylenated, of maltose, of PPO-PEO.
[0053] In the case of a mixture between nonionic surfactants and
cationic surfactants, the respective proportions thereof, by
weight, will be from 99/1 and 1/99.
[0054] The amount of surfactants forming the micelles will be
dependent on the CMC of the latter. However, in the context of the
invention, the concentration of micellar surfactants will range
from 0.1 to 10%, and preferably from 0.2 to 5%, by weight relative
to the total weight of the composition.
[0055] Block Polymer Micelles:
[0056] The micelles of amphiphilic block polymers can be prepared
according to the method described in WO 04/035013.
[0057] The block copolymers used for the preparation of the
micelles associated with the dsRNAs according to the invention are
in particular amphiphilic block polymers which are preferably
nonionic, diblock or triblock, and which can form micelles on
contact with water. They are in particular of diblock (A-B) or
triblock (A-B-A) type, A corresponding to a nonionic hydrophilic
polymeric block and B to a hydrophobic polymeric block. The
molecular weight of the polymers can be from 1000 and 100 000 and
the A/B ratio can be from 1/100 and 50/1.
[0058] In the context of the invention, three types of micelles can
be used: [0059] micelles of a cationic amphiphilic block polymer;
[0060] mixed micelles of a nonionic amphiphilic block polymer
associated with a cationic amphiphilic block polymer; and [0061]
mixed micelles of a nonionic amphiphilic block polymer associated
with a cationic surfactant.
[0062] The nonionic hydrophilic polymeric block can be selected
from polyethylene oxide (PEO) and polyvinylpyrrolidone (PVP).
[0063] The hydrophobic polymeric block can be selected from
polystyrene, poly(tert-butylstyrene), poly(methyl methacrylate),
poly(ethyl acrylate), poly(butyl acrylate), poly(butyl
methacrylate), poly(vinyl acetate), polycaprolactones,
polycaprolactams, polydimethylsiloxanes, poly(C.sub.3-C.sub.6
alkylene oxide)s, poly(aspartic acid), poly(lactic acid),
poly(glycolic acid), polyleucine, polybutadienes, polyethylenes,
polypropylenes, polybutylenes.
[0064] The block copolymer is preferably selected from among the
following block copolymers: [0065] polypropylene oxide/polyethylene
oxide [0066] polystyrene/polyoxyethylene [0067] poly(methyl
methacrylate)/polyoxyethylene [0068] poly(butyl
methacrylate)/polyoxyethylene [0069]
polyoxybutylene/polyoxyethylene [0070]
polycaprolactone/polyoxyethylene [0071]
polyethylene/polyoxyethylene [0072]
polyoxyethylene/polyoxybutylene/polyoxyethylene.
[0073] In the context of the invention, it is necessary to add to
the micellar composition: [0074] a cationic amphiphilic block
polymer, one of the blocks of which is cationic and can be
selected, by way of example, from among: [0075]
poly(trimethylethylammonium methacrylate); [0076] quaternized
poly(dimethylaminoethyl methacrylate); [0077]
polymethylvinylimidazolium; [0078]
poly(vinylbenzyltrimethylammonium chloride).
[0079] The association of a nonionic amphiphilic block polymer with
a cationic amphiphilic block polymer is such that the ratio between
the two will range from 99/1 to 1/99; and/or [0080] at least one
cationic surfactant as listed hereinafter.
[0081] In this case, the respective ratio of the nonionic
amphiphilic block polymer to the cationic surfactant will range
from 50/50 to 99/1.
[0082] In the context of the invention, the concentration of
micellar block polymers, which may or may not be associated with a
cationic surfactant, will range from 0.1 to 10%, and preferably
from 0.2 to 5%, by weight relative to the total weight of the
composition.
[0083] In one embodiment of the invention, it is also possible to
form micelles consisting of cationic amphiphilic block polymers as
described above.
[0084] Liposomes and Niosomes:
[0085] The nonionic amphiphilic lipids capable of forming nonionic
liposomes are in particular those described in EP-0-582,503.
[0086] In particular, the nonionic amphiphilic lipids can be a
mixture of esters of at least one polyol selected from the group
consisting of polyethylene glycol having from 1 to 60 ethylene
oxide units, sorbitan, sorbitan bearing 2 to 60 ethylene oxide
units, glycerol bearing 2 to 30 ethylene oxide units, polyglycerols
containing 2 to 15 glycerol units, sucroses, glucoses bearing 2 to
30 ethylene oxide units, and of at least one fatty acid containing
a linear or branched, saturated or unsaturated C.sub.5-C.sub.17
alkyl chain, the number of alkyl chains per polyol group ranging
from 1 to 10.
[0087] The expression "mixture of esters" covers not only mixtures
of pure esters of different chemical families, but also covers any
product which contains several chemically pure esters of a polyol
of the same family in variable proportions. This is, in particular,
the case of products having a statistical formula, in their
hydrophilic portion, for example a polyglyceryl ester of formula
CO--(OCH.sub.2--CHOH--CH.sub.2).sub.n--OH where n is a statistical
value and which can contain various proportions of esters for which
n=1, n=2, n=3, n=4, etc.; it is also the case of esters containing
several alkyl chains in their lipophilic portion, such as cocoates,
which contain C.sub.5 to C.sub.17 alkyl chains, or isostearates,
where the C.sub.17 alkyl chains are a complex mixture of isomeric
forms; it is also the case of products consisting of mixtures of
mono-, di-, tri- or polyesters of the same polyol. It should be
noted that a product which contains only a single ester capable of
forming vesicles and impurities of another type cannot be used
according to the invention.
[0088] Commercial esters which can be used alone according to the
invention, because they are in reality mixtures of esters, are, for
example, as follows: [0089] the partial esters of sorbitan (or
sorbitol anhydride) and of a fatty acid, marketed under the
trademarks "SPAN 20, 40, 60 and 80" by "ICI"; [0090] the sorbitan
isostearate marketed under the trademark "SI 10 R NIKKOL" by
"NIKKO"; [0091] the sorbitan stearate bearing 4 ethylene oxide
units, marketed under the trademark "TWEEN 61" by "ICI"; [0092] the
polyethylene glycol stearate containing 8 ethylene oxide units,
marketed under the trademark "MYR J 45" by "ICI"; [0093] the
polyethylene glycol monostearate of formula EMI6.1, in which
formula n is equal to 4, marketed under the trademark "MYS 4" by
"NIKKO"; [0094] the polyethylene glycol stearate, molecular weight
400, chemical quality or quality produced by biotechnology,
marketed by "UNICHEMA"; [0095] the diglyceryl stearate bearing 4
ethylene oxide units, marketed under the trademark "HOSTACERINE
DGS" by "HOECHST"; [0096] the tetraglyceryl stearate marketed under
the trademark "TETRAGLYN 1S" by "NIKKO"; [0097] the diglyceryl
isostearate, marketed by "SOLVAY"; [0098] the diglyceryl distearate
marketed under the trademark "EMALEX DSG 2" by "NIHON"; [0099] the
sucrose mono-, di- and tripalmitostearates marketed under the
trademarks "F50, F70, F110 and F160 CRODESTA" by "CRODA"; [0100]
the mixture of sucrose monopalmitostearate and sucrose
dipalmitostearate, marketed under the trademark "GRILLOTEN PSE 141
G" by "GRILLO"; [0101] the mixture of sucrose stearate and sucrose
cocoate, marketed under the trademark "ARLATONE 2121" by "ICI";
[0102] the methylglucose distearate bearing 20 ethylene oxide
units, marketed under the trademark "GLUCAM E 20 DISTEARATE" by
"AMERCHOL".
[0103] Mixtures of these products, which are already mixtures, with
one another, or mixtures of these products with pure products can,
of course, be used.
[0104] The cationic surfactants are advantageously selected from
the list hereinafter and such that they confer on the dispersion a
pH of from 5 to 8; the weight ratio of the amount of nonionic
amphiphilic lipids to the amount of cationic surfactants in the
lipid phase being from 50/1 to 50/25, and the weight ratio of the
lipid phase to the aqueous phase of a dispersion being from 1/1000
to 300/1000.
[0105] Oleosomes:
[0106] The oleosomes relating to the invention are described in
EP-0-705,593. They involve an emulsion of the oil-in-water type
made up of oily globules provided with a lamellar liquid crystal
coating, dispersed in an aqueous phase, characterized in that each
oily globule is, as a unit, coated with a monolamellar or
oligolamellar layer (1 to 10 sheets that can be visualized by
transmission electron microscopy after cryofracture) obtained from
at least one lipophilic surfactant, at least one hydrophilic
surfactant and at least one cationic surfactant conferring on the
emulsion a pH ranging from 5 to 8, the coated oily globules having
an average diameter of less than 500 nanometers.
[0107] The lipophilic surfactant and the hydrophilic surfactant
each contain at least one saturated fatty chain having more than
approximately 12 carbon atoms. Even more preferably, this fatty
chain contains from 16 to 22 carbon atoms.
[0108] According to another preferred embodiment of the invention,
the lipophilic surfactant has an HLB of from approximately 2 to
approximately 5. As is well known, the term HLB
(Hydrophilic-Lipophilic Balance) means the balance between the size
and the strength of the hydrophilic group and the size and the
strength of the lipophilic group of the surfactant.
[0109] Examples of such lipophilic surfactants are sucrose
distearate, diglyceryl distearate, tetraglyceryl tristearate,
decaglyceryl decastearate, diglyceryl monostearate, hexaglyceryl
tristearate, decaglyceryl pentastearate, sorbitan monostearate,
sorbitan tristearate, diethylene glycol monostearate, the glyceryl
ester of palmitic acid and stearic acid, polyoxyethylenated
monostearate 2 OE (comprising 2 oxyethylene units), glyceryl
monobehenate and dibehenate, and pentaerythritol tetrastearate.
[0110] The hydrophilic surfactant preferably has an HLB of from
approximately 8 to approximately 12.
[0111] As examples of such hydrophilic surfactants, mention may be
made of the following compounds: polyoxyethylenated sorbitan
monostearate 4 OE, polyoxyethylenated sorbitan tristearate 20 OE,
polyoxyethylenated monostearate 8 OE, hexaglyceryl monostearate,
polyoxyethylenated monostearate 10 OE, polyoxyethylenated
distearate 12 OE and polyoxyethylenated methylglucose distearate 20
OE.
[0112] The cationic surfactants can advantageously be selected from
among the compounds mentioned hereinafter.
[0113] Nanoemulsions:
[0114] The cationic particles can also be selected from
oil-in-water nanoemulsions comprising an oily phase dispersed in an
aqueous phase, the oil globules of which have a number-average size
of less than 100 nm, characterized in that they comprise at least
one amphiphilic lipid comprising at least one nonionic amphiphilic
lipid and a cationic amphiphilic lipid, the oily phase and the
amphiphilic lipids being present at a content such that the oily
phase/amphiphilic lipid weight ratio ranges from 3 to 10.
[0115] The nanoemulsions generally have a transparent to bluish
appearance. The transparency of said nanoemulsions is measured by
means of a coefficient of transmittance at 600 nm ranging from 10
to 90%, or else by means of turbidity. The turbidity of the
compositions of the invention ranges from 60 to 400 NTU, and
preferably from 70 to 300 NTU, which turbidity is measured using a
HACH portable turbidity meter--model 2100 P at approximately
25.degree. C.
[0116] The oil globules of the nanoemulsions of the invention have
a number-average size of less than 100 nm, and preferably ranging
from 20 to 80 nm, and more preferably from 40 to 60 nm. Decreasing
the size of the globules makes it possible to promote penetration
of the active agents into the superficial layers of the skin
(carrier effect).
[0117] The nanoemulsions in accordance with the invention are
preferably prepared at temperatures ranging from 4 to 45.degree. C.
and are thus compatible with thermosensitive active agents.
[0118] These dispersions are in particular described in the
following applications: EP-0-728,460, EP-0-879,589, EP-1-010,413,
EP-1-010,414, EP-1-010,416, EP-1-013,338, EP-1-016,453,
EP-1-018,363, EP-1-025,898 and EP-1-120,102. In all of these
applications, it is specified that, in order to improve particle
stability, an ionic surfactant will be added to the nonionic
surfactant (or mixture).
[0119] In the case of the present application, one or more cationic
surfactants will be exclusively used as ionic surfactant.
[0120] The proportions indicated in the references above are to be
conserved and, by way of example of a cationic surfactant, the list
common to all the particles will be selected.
[0121] The nonionic surfactants, preferably water-soluble or
water-dispersible, contain at least one hydrophobic block and at
least one hydrophilic block.
[0122] The nonionic amphiphilic lipids of the invention are
preferably selected from among: [0123] 1/ silicone surfactants,
[0124] 2/ amphiphilic lipids which are liquid at a temperature less
than or equal to 45.degree. C., selected from esters of at least
one polyol or at least one fatty acid containing at least one
linear or branched, saturated or unsaturated, and in particular
unsaturated or branched, C.sub.8-C.sub.22 alkyl chain, the polyol
being selected from the group consisting of polyethylene glycol
having from 1 to 60 ethylene oxide units, sorbitan, glycerol which
may contain from 2 to 30 ethylene oxide units, and polyglycerols
having from 2 to 15 glycerol units, [0125] 3/ esters of a fatty
acid and of a sugar and ethers of a fatty alcohol and of a sugar,
[0126] 4/ surfactants which are solid at a temperature equal to
45.degree. C., selected from among glycerol fatty esters, sorbitan
fatty esters and oxyethylenated sorbitan fatty esters, ethoxylated
fatty ethers and ethoxylated fatty esters, [0127] 5/ block
copolymers of ethylene oxide (A) and of propylene oxide (B), and
mixtures of these surfactants. [0128] 1/ The silicone surfactants
which can be used according to the invention are silicone compounds
containing at least one oxyethylenated chain --OCH.sub.2CH.sub.2--
and/or oxypropylenated chain --OCH.sub.2CH.sub.2CH.sub.2--;
exemplary are those described in U.S. Pat. Nos. 5,364,633 and
5,411,744.
[0129] Preferably, the silicone surfactant used according to the
present invention is a compound of formula (II): ##STR1## in
which:
[0130] R.sub.1, R.sub.2 and R.sub.3, independently of one another,
represent a C.sub.1-C.sub.6 alkyl radical or a
--(CH.sub.2).sub.x--(OCH.sub.2CH.sub.2).sub.y(OCH.sub.2CH.sub.2CH.sub.2).-
sub.z--OR.sub.4 radical, at least one radical R.sub.1, R.sub.2 or
R.sub.3 not being an alkyl radical; R.sub.4 being hydrogen, an
alkyl radical or an acyl radical;
[0131] A is an integer ranging from 0 to 200;
[0132] B is an integer ranging from 0 to 50; with the proviso that
A and B are not equal to zero at the same time;
[0133] x is an integer ranging from 1 to 6;
[0134] y is an integer ranging from 1 to 30;
[0135] z is an integer ranging from 0 to 5.
[0136] According to another preferred embodiment of the invention,
in the compound of formula (X), the alkyl radical is a methyl
radical, x is an integer ranging from 2 to 6 and y is an integer
ranging from 4 to 30.
[0137] By way of example of silicone surfactants of formula (II),
representative are the compounds of formula (III): ##STR2## in
which A is an integer ranging from 20 to 105, B is an integer
ranging from 2 to 10 and y is an integer ranging from 10 to 20.
[0138] By way of example of silicone surfactants of formula (II),
mention may also be made of the compounds of formula (IV):
H--(OCH.sub.2CH.sub.2).sub.y--(CH.sub.2).sub.3--[(CH.sub.3).sub.2SiO].sub-
.A--(CH.sub.2).sub.3--(OCH.sub.2CH.sub.2).sub.y--OH (IV) in which
A' and y are integers ranging from 10 to 20.
[0139] As silicone surfactants, use may particularly be made of
those marketed by Dow Corning under the trademarks DC 5329, DC
7439-146, DC 2-5695 and Q4-3667. The compounds DC 5329, DC 7439-146
and DC 2-5695 are compounds of formula (XI) where, respectively, A
is 22, B is 2 and y is 12; A is 103, B is 10 and y is 12; A is 27,
B is 3 and y is 12.
[0140] The compound Q4-3667 is a compound of formula (IV) where A
is 15 and y is 13. [0141] 2/ The amphiphilic lipids which are
liquid at a temperature less than or equal to 45.degree. C. can in
particular be selected from among: [0142] the polyethylene glycol
isostearate of molar weight 400 (CTFA name: PEG-8 Isostearate),
marketed under the trademark Prisorine 3644 by UNICHEMA; [0143] the
diglyceryl isostearate marketed by SOLVAY; [0144] the polyglyceryl
laurate containing 2 glycerol units (polyglyceryl-2 laurate),
marketed under the trademark Diglycerin-monolaurate by SOLVAY;
[0145] the sorbitan oleate marketed under the trademark SPAN 80 by
ICI; [0146] the sorbitan isostearate marketed under the trademark
NIKKOL SI 10R by NIKKO; [0147] the .alpha.-butylglucoside cocoate
or the .alpha.-butylglucoside caprate marketed by ULICE. [0148] 3/
The esters of a fatty acid and of a sugar, which can be used as
nonionic amphiphilic lipids in a nanoemulsion according to the
invention, are preferably solid at a temperature of less than or
equal to 45.degree. C. and can be selected in particular from among
the group comprising esters or mixtures of esters of a
C.sub.8-C.sub.22 fatty acid and of sucrose, of maltose, of glucose
or of fructose, and esters or mixtures of esters of a
C.sub.14-C.sub.22 fatty acid and of methylglucose.
[0149] The C.sub.8-C.sub.22 or C.sub.14-C.sub.22 fatty acids which
form the fatty unit of the esters which can be used in the
nanoemulsion of the invention contain a saturated or unsaturated
linear alkyl chain having, respectively, from 8 to 22 or from 14 to
22 carbon atoms. The fatty unit of the esters can in particular be
selected from stearates, behenates, arachidonates, palmitates,
myristates, laurates, caprates and mixtures thereof. Stearates are
preferably used.
[0150] By way of example of esters or of mixtures of esters of a
fatty acid and of sucrose, of maltose, of glucose or of fructose,
representative are sucrose monostearate, sucrose distearate,
sucrose tristearate and mixtures thereof, such as the products
marketed by Croda under the trademark Crodesta F50, F70, F110 and
F160 having, respectively, an HLB (Hydrophilic-Lipophilic Balance)
of 5, 7, 11 and 16; and by way of example of esters or of mixtures
of esters of a fatty acid and of methylglucose, mention may be made
of polyglyceryl-3 methylglucose distearate, marketed by Goldschmidt
under the trademark Tego-care 450. Mention may also be made of
monoesters of glucose or of maltose such as methyl
o-hexadecanoyl-6-D-glucoside and o-hexadecanoyl-6-D-maltoside.
[0151] The ethers of a fatty alcohol and of a sugar, which can be
used as nonionic amphiphilic lipids in the nanoemulsion according
to the invention, are solid at a temperature of less than or equal
to 45.degree. C. and can be selected in particular from among the
group comprising ethers or mixtures of ethers of a C.sub.8-C.sub.22
fatty alcohol and of glucose, of maltose, of sucrose or of
fructose, and ethers or mixtures of ethers of a C.sub.14-C.sub.22
fatty alcohol and of methylglucose. They are in particular
alkylpolyglucosides.
[0152] The C.sub.8-C.sub.22 or C.sub.14-C.sub.22 fatty alcohols
which form the fatty unit of the ethers which can be used in the
nanoemulsion of the invention contain a saturated or unsaturated
linear alkyl chain having, respectively, from 8 to 22 or from 14 to
22 carbon atoms. The fatty unit of the ethers can in particular be
selected from decyl, cetyl, behenyl, arachidyl, stearyl, palmityl,
myristyl, lauryl, capryl and hexadecanoyl units, and mixtures
thereof such as cetearyl.
[0153] By way of example of ethers of a fatty alcohol and of a
sugar, mention may be made of alkylpolyglucosides such as
decylglucoside and laurylglucoside, marketed, for example, by
Henkel under the respective trademarks Plantaren 2000 and Plantaren
1200, cetostearylglucoside optionally as a mixture with cetostearyl
alcohol, marketed, for example, under the trademark Montanov 68 by
Seppic, under the trademark Tego-care CG90 by Goldschmidt and under
the trademark Emulgade KE3302 by Henkel, and arachidylglucoside,
for example in the form of the mixture of arachidyl and behenyl
alcohols and of arachidylglucoside, marketed under the trademark
Montanov 202 by Seppic.
[0154] As a nonionic amphiphilic lipid of this type, use is more
particularly made of sucrose monostearate, sucrose distearate,
sucrose tristearate and mixtures thereof, polyglyceryl-3
methylglucose distearate and alkylpolyglucosides. [0155] 4/ The
glycerol fatty esters which can be used as nonionic amphiphilic
lipids in the nanoemulsion according to the invention, which are
solid at a temperature of less than or equal to 45.degree. C., can
be selected in particular from the group comprising the esters
formed from at least one acid containing a saturated linear alkyl
chain having from 16 to 22 carbon atoms, and from 1 to 10 glycerol
units. One or more of these glycerol fatty esters can be used in
the nanoemulsion of the invention.
[0156] These esters can in particular be selected from among
stearates, behenates, arachidates, palmitates and mixtures thereof.
Stearates and palmitates are preferably used.
[0157] By way of example of a surfactant which can be used in the
nanoemulsion of the invention, mention may be made of decaglyceryl
(10 units of glycerol) monostearate, distearate, tristearate and
pentastearate (CTFA names: Polyglyceryl-10 stearate,
Polyglyceryl-10 distearate, Polyglyceryl-10 tristearate,
Polyglyceryl-10 pentastearate), such as the products marketed under
the respective trademarks Nikkol Decaglyn 1-S, 2-S, 3-S and 5-S by
Nikko, and diglyceryl monostearate (CTFA name: Polyglyceryl-2
stearate) such as the product marketed by Nikko under the trademark
Nikkol DGMS.
[0158] The sorbitan fatty esters which can be used as nonionic
amphiphilic lipids in the nanoemulsion according to the invention,
which are solid at a temperature of less than or equal to
45.degree. C., are selected in particular from among the group
comprising esters of a C.sub.16-C.sub.22 fatty acid and of sorbitan
and oxyethylenated esters of a C.sub.16-C.sub.22 fatty acid and of
sorbitan. They are formed from at least one fatty acid containing
at least one saturated linear alkyl chain having respectively from
16 to 22 carbon atoms, and from sorbitol or ethoxylated sorbitol.
The oxyethylenated esters generally contain from 1 to 100 ethylene
oxide units, and preferably from 2 to 40 ethylene oxide (EO)
units.
[0159] These esters can in particular be selected from among
stearates, behenates, arachidates, palmitates, and mixtures
thereof. Stearates and palmitates are preferably used.
[0160] By way of example of a sorbitan fatty ester and of an
oxyethylenated sorbitan fatty ester, which can be used in the
nanoemulsion of the invention, representative are the sorbitan
monostearate (CTFA name: Sorbitan stearate) marketed by ICI under
the trademark Span 60, the sorbitan monopalmitate (CTFA name:
Sorbitan palmitate) marketed by ICI under the trademark Span 40,
and the sorbitan tristearate 20 EO (CTFA name: Polysorbate 65)
marketed by ICI under the trademark Tween 65.
[0161] The ethoxylated fatty ethers which are solid at a
temperature of less than or equal to 45.degree. C., which can be
used as nonionic amphiphilic lipids in the nanoemulsion according
to the invention, are preferably ethers formed from 1 to 100
ethylene oxide units and from at least one fatty alcohol chain
having from 16 to 22 carbon atoms. The fatty chain of the ethers
can in particular be selected from among behenyl, arachidyl,
stearyl and cetyl units, and mixtures thereof such as cetearyl. By
way of example of ethoxylated fatty ethers, mention may be made of
ethers of behenyl alcohol comprising 5, 10, 20 and 30 ethylene
oxide units (CTFA names: Beheneth-5, Beheneth-10, Beheneth-20,
Beheneth-30), such as the products marketed under the trademarks
Nikkol BB5, BB10, BB20 and BB30 by Nikko, and the ether of stearyl
alcohol comprising 2 ethylene oxide units (CTFA name: Steareth-2),
such as the product marketed under the trademark Brij 72 by
ICI.
[0162] The ethoxylated fatty esters which are solid at a
temperature of less than or equal to 45.degree. C., which can be
used as nonionic amphiphilic lipids in a nanoemulsion according to
the invention, are esters formed from 1 to 100 ethylene oxide units
and from at least one fatty acid chain having from 16 to 22 carbon
atoms. The fatty chain of the esters can in particular be selected
from among stearate, behenate, arachidate and palmitate units, and
mixtures thereof. By way of example of ethoxylated fatty esters,
mention may be made of the ester of stearic acid comprising 40
ethylene oxide units, such as the product marketed under the
trademark Myrj 52 (CTFA name: PEG-40 stearate) by ICI and also the
ester of behenic acid comprising 8 ethylene oxide units (CTFA name:
PEG-8 behenate), such as the product marketed under the trademark
Compritol HD5 ATO by Gattefosse. [0163] 5/ The block copolymers of
ethylene oxide and of propylene oxide, which can be used as
nonionic amphiphilic lipids in the nanoemulsion according to the
invention, can be selected in particular from among the block
copolymers of formula (V):
HO(C.sub.2H.sub.4O)x(C.sub.3H.sub.6O)y(C.sub.2H.sub.4O)zH (V) in
which x, y and z are integers such that x+z ranges from 2 to 100
and y ranges from 14 to 60, and mixtures thereof, and more
particularly from the block copolymers of formula (V) having an HLB
ranging from 2 to 16.
[0164] These block copolymers can in particular be selected from
among poloxamers, and in particular from Poloxamer 231 such as the
product marketed by ICI under the trademark Pluronic L81 of formula
(V) with x=z=6, y=39 (HLB 2); Poloxamer 282 such as the product
marketed by ICI under the trademark Pluronic L92 of formula (V)
with x=z=10, y=47 (HLB 6); and Poloxamer 124 such as the product
marketed by ICI under the trademark Pluronic L44 of formula (V)
with x=z=11, y=21 (HLB 16).
[0165] As nonionic amphiphilic lipids, representative are the
mixtures of nonionic surfactants described in EP-A-705593,
incorporated herein for reference.
[0166] Among the nonionic amphiphilic lipids, use may in particular
be made of: [0167] PEG 400 isostearate or PEG-8 isostearate
(containing 8 mol of ethylene oxide), [0168] diglyceryl
isostearate, [0169] polyglyceryl monolaurate containing 2 units of
glycerol and polyglyceryl stearates containing 10 units of
glycerol, [0170] sorbitan oleate, [0171] sorbitan isostearate, and
mixtures thereof.
[0172] The nonionic amphiphilic lipids can be present in the
nanoemulsion according to the invention at a content ranging from
0.2% to 12% by weight, relative to the total weight of the
composition, and preferably ranging from 0.2% to 8% by weight, and
preferentially ranging from 0.2% to 6% by weight.
[0173] The cationic amphiphilic lipids are selected from the list
given hereinafter.
[0174] They are present in the nanoemulsions of the invention,
preferably, in concentrations ranging from 0.01 to 6% by weight
relative to the total weight of the nanoemulsion, and more
particularly from 0.2 to 4% by weight.
[0175] Oils:
[0176] The oily phase of the nanoemulsions according to the
invention comprise at least one oil. The oils which can be used in
the nanoemulsions of the invention are preferably selected from the
group consisting of: [0177] oils of animal or plant origin, made up
of esters of fatty acids and of polyols, in particular liquid
triglycerides, for example sunflower oil, corn oil, soybean oil,
avocado oil, jojoba oil, marrow oil, grapeseed oil, sesame seed
oil, hazelnut oil, fish oils and glyceryl tricaprocaprylate, or
plant or animal oils of formula R.sub.9COOR.sub.10 in which R.sub.9
is a higher fatty acid residue having from 7 to 29 carbon atoms and
R.sub.10 is a linear or branched hydrocarbon-based chain having
from 3 to 30 carbon atoms, in particular alkyl or alkenyl, for
example purcellin oil or liquid jojoba wax; [0178] natural or
synthetic essential oils, such as, for example, eucalyptus oil,
lavandin oil, lavender oil, vetiver oil, litsea cubeba oil, lemon
oil, sandlewood oil, rosemary oil, camomile oil, savoury oil,
nutmeg oil, cinnamon oil, hyssop oil, caraway oil, orange oil,
geraniol oil, cade oil and bergamot oil; [0179] synthetic oils such
as parleam oil, polyolefins and liquid carboxylic acid esters;
[0180] mineral oils such as hexadecane, isohexadecane and paraffin
oil; [0181] halogenated oils, in particular fluorocarbons such as
fluoroamines, for example perfluorotributylamine,
fluorohydrocarbons, for example perfluorodecahydronaphthalene,
fluoro esters and fluoro ethers; [0182] volatile or non-volatile
silicone oils.
[0183] The polyolefins which can be used as synthetic oils are in
particular poly-.alpha.-oleflns, and more particularly those of
hydrogenated or non-hydrogenated polybutene type, and preferably
hydrogenated or non-hydrogenated polyisobutene type.
[0184] The liquid carboxylic acid esters which can be used as
synthetic oils may be monocarboxylic, dicarboxylic, tricarboxylic,
or tetracarboxylic acid esters. The total number of carbons in the
esters is generally greater than or equal to 10, and preferably
less than 100, and more particularly less than 80. They are in
particular monoesters of saturated or unsaturated, linear or
branched C.sub.1-C.sub.26 aliphatic acids and of saturated or
unsaturated, linear or branched C.sub.1-C.sub.26 aliphatic
alcohols, the total number of carbons in the esters generally being
greater than or equal to 10. Use may also be made of esters of
C.sub.4-C.sub.22 dicarboxylic or tricarboxylic acids and of
C.sub.1-C.sub.22 alcohols and esters of monocarboxylic,
dicarboxylic or tricarboxylic acids and of C.sub.2-C.sub.26
dihydroxy, trihydroxy, tetrahydroxy or pentahydroxy alcohols.
[0185] Among the esters mentioned above, use is preferably made of
alkyl palmitates such as ethyl palmitate, isopropyl palmitate,
2-ethylhexyl palmitate, 2-octyldecyl palmitate; alkyl myristates
such as isopropyl myristate, butyl myristate, cetyl myristate,
2-octyidodecyl myristate; alkyl stearates such as hexyl stearate,
butyl stearate, isobutyl stearate; alkyl malates such as dioctyl
malate; alkyl laurates such as hexyl laurate and 2-hexyldecyl
laurate; isononyl isononanoate; cetyl octanoate.
[0186] Advantageously, the nanoemulsions according to the invention
contain at least one oil of molecular weight greater than or equal
to 400, in particular ranging from 400 to 10 000, better still
ranging from 400 to 5000, or even ranging from 400 to 2500. The
oils of molecular weight greater than or equal to 400 can be
selected from oils of animal or plant origin, mineral oils,
synthetic oils and silicone oils, and mixtures thereof. As oils of
this type, mention may, for example, be made of isocetyl palmitate,
isocetyl stearate, avocado oil and jojoba oil.
[0187] The nanoemulsions in accordance with the invention comprise
an amount of oily phase (oil and other fatty substances besides the
amphiphilic lipid) preferably ranging from 2 to 40% by weight
relative to the total weight of the nanoemulsion, and more
particularly from 4 to 30% by weight, and preferably from 4 to 20%
by weight.
[0188] The oily phase and the amphiphilic lipids (nonionic and
ionic amphiphilic lipids) are preferably present in the
nanoemulsions according to the invention according to a weight
ratio of the amount of oily phase to the amount of amphiphilic
lipid ranging from 3 to 10, and preferably ranging from 3 to 6. The
term "amount of oily phase" means the total amount of the
constituents of this oily phase without including the amount of
amphiphilic lipid. The nanoemulsions in accordance with the present
invention can contain, in addition to the urea derivatives of
formula (I) described above, solvents, in particular for improving,
if necessary, the transparency of the composition.
[0189] These solvents are preferably selected from the group
consisting of: [0190] C.sub.1-C.sub.8 lower alcohols such as
ethanol; [0191] glycols such as glycerol, propylene glycol,
1,3-butylene glycol, dipropylene glycol, or polyethylene glycols
having from 4 to 16 ethylene oxide units, and preferably from 8 to
12; [0192] sugars such as glucose, fructose, maltose, lactose or
sucrose.
[0193] These solvents can be used as a mixture. When they are
present in the nanoemulsions of the invention, they can be used at
concentrations preferably ranging from 0.01 to 30% by weight
relative to the total weight of the nanoemulsion, and better still
from 5 to 20% by weight relative to the total weight of the
nanoemulsion. The amount of alcohol(s) and/or of sugar(s)
preferably ranges from 5 to 20% by weight relative to the total
weight of the nanoemulsion and the amount of glycol(s) preferably
ranges from 5 to 15% by weight relative to the total weight of the
nanoemulsion.
[0194] Method of Preparation:
[0195] The method of preparing a nanoemulsion as defined above
entails mixing the aqueous phase containing the urea derivative and
the oily phase, with vigorous stirring, at a temperature ranging
from 10.degree. C. to 80.degree. C., and in carrying out a
high-pressure homogenization step at a pressure of greater than
5.times.10.sup.7 Pa and in optionally adding the polymer used.
According to a preferred embodiment of the invention, another
high-pressure homogenization step is subsequently carried out at a
pressure of greater than 5.times.10.sup.7 Pa. The high-pressure
homogenization is preferably carried out at a pressure ranging from
6.times.10.sup.7 Pa to 18.times.10.sup.7 Pa. The shear preferably
ranges from 2.times.10.sup.6 s.sup.-1 to 5.times.10.sup.8 s.sup.-1,
and better still from 1.times.10.sup.8 s.sup.-1 to 3.times.10.sup.8
s.sup.1 (s.sup.-1 signifies second.sup.-1). Such a method makes it
possible to produce nanoemulsions compatible with thermosensitive
active compounds, which may contain oils and in particular
fragrances which contain fatty substances, without denaturing
them.
[0196] Nanocapsules:
[0197] The nanocapsules relating to the invention are those
described in EP-0-447,318, EP-0-557,489, EP-0-780,115,
EP-1-025,901, EP-1-029,587, EP-1-034,839, EP-1-414,390,
FR-2,830,776, EP-1-342,471, FR-2,848,879 and FR 04/50057.
[0198] The nanocapsules are Core-Shell particles having an oily
core and a polymeric shell. The various applications mentioned
above relate to various families of polymers and various methods
for obtaining them. The size of the capsules is always less than 1
.mu.m and it is possible to have sizes of less than 80 nm. These
particles can be coated with a lamellar liquid crystal phase most
commonly consisting of a lecithin or of a dimethicone copolyol. The
coating must be an amphiphilic lipid capable of spontaneously
forming a lamellar liquid crystal phase on contact with water. It
is to this amphiphilic lipid capable of forming a lamellar phase
that the cationic surfactant which will confer on the particles
(the nanocapsule) a positive zeta potential will be added. The
weight ratio of the amphiphilic lipid forming the lamellar phase to
the cationic surfactant will be from 99/1 and 75/25.
[0199] The cationic surfactants which can be used are those listed
hereinafter.
[0200] Organic Particles:
[0201] The organic particles of the invention are solid
nanospheres, which do not have an internal cavity, formed by
various methods (dispersion in water, nanoprecipitation,
microemulsion, etc.) and composed of at least one polymer or of at
least one copolymer, or of a mixture thereof. The particle is
cationic, with the zeta potential defined above, either because the
polymer(s) or copolymer(s) is (are) cationic, or because it (they)
is (are) nonionic and a cationic surfactant as described
hereinafter is used. In relation to the polymer, the amount of
cationic surfactant will be from 0 and 25%.
[0202] Inorganic Particles:
[0203] The cationic inorganic particles of the invention may, by
way of example, be based on silica, TiO.sub.2, ZnO, alumina, etc.
By way of example, representative are alumina particles in a
colloidal dispersion in water, such as the Nanomer 2 particles from
Nalco. Clariant and Grace also provide particles of this type.
[0204] Cationic Surfactants which can be Used for the Preparation
of the Cationic Particles of the Invention:
[0205] The cationic surfactants which can be used according to the
invention are listed hereinafter, this list being non-limiting.
[0206] The cationic amphiphilic lipids are preferably selected from
the group consisting of quaternary ammonium salts and fatty amines
and their salts.
[0207] The quaternary ammonium salts are, for example: [0208] those
which have the following general formula (IV): ##STR3## in which
the radicals R.sub.1 to R.sub.4, which may be identical or
different, represent a linear or branched aliphatic radical having
from 1 to 30 carbon atoms, or an aromatic radical such as aryl or
alkylaryl. The aliphatic radicals can contain heteroatoms such as,
in particular, oxygen, nitrogen, sulfur or halogens. The aliphatic
radicals are, for example, selected from among the following
radicals: alkyl, alkoxy, polyoxy(C.sub.2-C.sub.6)alkylene,
alkylamide, (C.sub.12-C.sub.22)alkylamido(C.sub.2-C.sub.6)alkyl,
(C.sub.12-C.sub.22)alkyl acetate, hydroxyalkyl, containing
approximately from 1 to 30 carbon atoms; X is an anion selected
from the group consisting of halides, phosphates, acetates,
lactates, (C.sub.2-C.sub.6)alkyl sulfates, and alkyl- or
alkylarylsulfonates, [0209] quaternary ammonium salts of
imidazolinium, such as, for example, that having the following
formula (V): ##STR4## in which R.sub.5 is an alkenyl or alkyl
radical having from 8 to 30 carbon atoms, for example derived from
tallow fatty acids, R.sub.6 is a hydrogen atom, a C.sub.1-C.sub.4
alkyl radical or an alkenyl or alkyl radical having from 8 to 30
carbon atoms, R.sub.7 is a C.sub.1-C.sub.4 alkyl radical, R.sub.8
is a hydrogen atom or a C.sub.1-C.sub.4 alkyl radical, and X is an
anion selected from the group consisting of halides, phosphates,
acetates, lactates, alkyl sulfates, and alkyl- or
alkylarylsulfonates. Preferably, R.sub.5 and R.sub.6 denote a
mixture of alkenyl or alkyl radicals having from 12 to 21 carbon
atoms, for example derived from tallow fatty acids, R.sub.7 denotes
methyl, and R.sub.8 denotes hydrogen. Such a product is, for
example, marketed under the trademark "REWOQUAT W 75" by REWO,
[0210] quaternary diammonium salts having the formula (VI):
##STR5## in which R.sub.9 denotes an aliphatic radical containing
approximately from 16 to 30 carbon atoms, R.sub.10, R.sub.11,
R.sub.12, R.sub.13 and R.sub.14, which may be identical or
different, are selected from hydrogen or an alkyl radical having
from 1 to 4 carbon atoms, and X is an anion selected from the group
consisting of halides, acetates, phosphates, nitrates and methyl
sulfates. Such quaternary diammonium salts comprise in particular
propanetallowdiammonium dichloride; [0211] quaternary ammonium
salts containing at least one ester function.
[0212] The quaternary ammonium salts containing at least one ester
function which can be used according to the invention are, for
example, those having the following formula (VII): ##STR6## in
which: [0213] R.sub.15 is selected from among C.sub.1-C.sub.6 alkyl
radicals and C.sub.1-C.sub.6 hydroxyalkyl or dihydroxyalkyl
radicals; [0214] R.sub.16 is selected from among: [0215] the
radical ##STR7## [0216] linear or branched, saturated or
unsaturated C.sub.1-C.sub.22 hydrocarbon-based radicals R.sub.20,
[0217] a hydrogen atom, [0218] R.sub.18 is selected from among:
[0219] the radical ##STR8## [0220] linear or branched, saturated or
unsaturated C.sub.1-C.sub.6 hydrocarbon-based radicals R.sub.22,
[0221] a hydrogen atom, [0222] R.sub.17, R.sub.19 and R.sub.21,
which may be identical or different, are selected from among linear
or branched, saturated or unsaturated C.sub.7-C.sub.21
hydrocarbon-based radicals; [0223] n, p and r, which may be
identical or different, are integers ranging from 2 to 6; [0224] y
is an integer ranging from 1 to 10; [0225] x and z, which may be
identical or different, are integers ranging from 0 to 10; [0226]
X.sup.- is a simple or complex organic or inorganic anion; with the
proviso that the sum x+y+z is from 1 to 15, that when x is 0, then
R.sub.16 denotes R.sub.20, and that when z is 0, then R.sub.18
denotes R.sub.22.
[0227] The alkyl radicals R.sub.15 may be linear or branched, and
more particularly linear.
[0228] Preferably, R.sub.15 denotes a methyl, ethyl, hydroxyethyl
or dihydroxypropyl radical, and more particularly a methyl or ethyl
radical. Advantageously, the sum x+y+z is from 1 to 10.
[0229] When R.sub.16 is a hydrocarbon-based radical R.sub.20, it
may be long and may contain from 12 to 22 carbon atoms, or may be
short and may contain from 1 to 3 carbon atoms.
[0230] When R.sub.18 is hydrocarbon-based radical R.sub.22, it
preferably contains 1 to 3 carbon atoms.
[0231] Advantageously, R.sub.17, R.sub.19 and R.sub.21, which may
identical or different, are selected from among linear or branched,
saturated or unsaturated C.sub.11-C.sub.21 hydrocarbon-based
radicals, and more particularly from linear or branched, saturated
or unsaturated C.sub.11-C.sub.21 alkyl or alkenyl radicals.
[0232] Preferably, x and z, which may be identical or different,
are 0 or 1.
[0233] Advantageously, y is equal to 1.
[0234] Preferably, n, p, and r, which may be identical or
different, are 2 or 3, and even more particularly are equal to
2.
[0235] The anion is preferably a halide (chloride, bromide or
iodide) or an alkyl sulfate, more particularly methyl sulfate. Use
may, however, be made of methanesulfonate, phosphate, nitrate,
tosylate, an anion derived from an organic acid such as acetate or
lactate, or any other anion compatible with the ammonium containing
an ester function.
[0236] The anion X.sup.-1 is even more particularly chloride or
methyl sulfate.
[0237] Use is more particularly made of the ammonium salts having
the formula (VII) in which: [0238] R.sub.15 denotes a methyl or
ethyl radical, [0239] x and y are equal to 1; [0240] z is equal to
0 or 1; [0241] n, p and rare equal to 2; [0242] R.sub.16 is
selected from among: [0243] the radical ##STR9## [0244] methyl,
ethyl or C.sub.14-C.sub.22 hydrocarbon-based radicals; [0245] a
hydrogen atom; [0246] R.sub.18 is selected from among: [0247] the
radical ##STR10## [0248] a hydrogen atom; R.sub.17, R.sub.19 and
R.sub.21, which may be identical or different, are selected from
among linear or branched, saturated or unsaturated
C.sub.13-C.sub.17 hydrocarbon-based radicals, and preferably from
linear or branched, saturated or unsaturated C.sub.13-C.sub.17
alkyl or alkenyl radicals.
[0249] Advantageously, the hydrocarbon-based radicals are
linear.
[0250] Mention may, for example, be made of the compounds having
the formula (VII) such as diacyloxyethyldimethylammonium,
diacyloxyethylhydroxyethylmethylammonium,
monoacyloxyethyldihydroxyethylmethylammonium,
triacyloxyethylmethylammonium and
monoacyloxyethylhydroxyethyldimethylammonium salts (chloride or
methyl sulfate, in particular), and mixtures thereof. The acyl
radicals preferably contain 14 to 18 carbon atoms, and originate
more particularly from a plant oil such as palm oil or sunflower
oil.
[0251] When the compound contains several acyl radicals, the latter
may be identical or different.
[0252] These products are obtained, for example, by direct
esterification of triethanolamine, of triisopropanolamine, of
alkyldiethanolamine or of alkyldiisopropanolamine, optionally
oxyalkylenated, on fatty acids or on mixtures of fatty acids of
plant or animal origin, or by transesterification of their methyl
esters. This esterification is followed by a quaternization using
an alkylating agent such as an alkyl halide (preferably, methyl or
ethyl halide), a dialkyl sulfate (preferably, methyl or ethyl
sulfate), methyl methanesulfonate, methyl para-toluenesulfonate,
glycol chlorohydrin or glycerol chlorohydrin.
[0253] Such compounds are, for example, marketed under the
trademarks DEHYQUART by HENKEL, STEPANQUAT by STEPAN, NOXAMIUM by
CECA and REWOQUAT WE 18 by REWOWITCO.
[0254] The compositions according to the invention preferably
contain a mixture of quaternary ammonium monoester, diester and
triester salts with a majority, by weight, being diester salts.
[0255] As a mixture of ammonium salts, use may, for example, be
made of the mixture containing 15 to 30% by weight of
acyloxyethyldihydroxyethylmethylammonium methyl sulfate, 45 to 60%
of diacyloxyethylhydroxyethylmethylammonium methyl sulfate and 15
to 30% of triacyloxyethylmethylammonium methyl sulfate, the acyl
radicals having from 14 to 18 carbon atoms and originating from
optionally partially hydrogenated palm oil. Use may also be made of
the ammonium salts containing at least one ester function described
in U.S. Pat. Nos. 4,874,554 and 4,137,180.
[0256] Among the quaternary ammonium salts having the formula (IV),
preference is given, firstly, to tetraalkylammonium chlorides, for
instance dialkyldimethylammonium or alkyltrimethylammonium
chlorides, in which the alkyl radical contains approximately from
12 to 22 carbon atoms, in particular behenyltrimethylammonium,
distearyidimethylammonium, cetyltrimethylammonium or
benzyldimethylstearylammonium chlorides, or else, secondly, the
stearamidopropyldimethyl (myristyl acetate) ammonium chloride
marketed under the trademark "CERAPHYL 70" by VAN DYK.
[0257] According to the invention, behenyltrimethylammonium
chloride or behenyltrimethylammonium bromide and CTAB
(cetyltrimethylammonium bromine) are the quaternary ammonium salts
most particularly preferred.
[0258] The fatty amines of the invention correspond to the general
formula: ##STR11## wherein: [0259] R.sub.1 is a branched or
unbranched, saturated or unsaturated hydrocarbon-based chain
containing from 8 and 30 carbon atoms, and preferably from 10 and
24; [0260] R.sub.2 and R.sub.3 are selected independently from
branched or unbranched, saturated or unsaturated hydrocarbons
containing from 1 to 10 carbon atoms, and preferably from 1 to 4;
[0261] R.sub.2 and R.sub.3 can also, still independently of one
another, correspond to a hydrogen atom H; [0262] M is from 1 to 10,
and preferably from 1 to 5.
[0263] By way of non-limiting examples, mention will be made of:
stearylamine, stearate aminoethylethanolamide, stearyl
diethanolamide, stearate diethylenetriamine,
stearamidopropyldimethylamine, stearamidopropyldiethylamine,
stearamidoethyldiethylamine, stearamidoethyldimethylamine,
palmitoamidopropyldimethylamine, palmitoamidopropyldiethylamine,
palmitoamidoethyldiethylamine, palmitoamidoethyldimethylamine,
behenamidopropyldimethylamine, behenamidopropyldiethylamine,
behenamidoethyldiethylamine, behenamidoethyldimethylamine,
arachidamidopropyldimethylamine, arachidamidopropyldiethylamine,
arachidamidoethyldiethylamine and
arachidamidoethyldimethylamine.
[0264] As a fatty amine which is commercially available, mention
may be made of Incromine BB from Croda, Amidoamine MSP from Nikkol,
and Lexamine from Inolex.
[0265] As other fatty amines, mention will, by way of example, be
made of stearylamine, stearate aminoethylethanolamide, stearyl
diethanolamide and stearate diethylenetriamine that, inter alia,
Sabo sells with the Sabomina series.
[0266] Mention will also be made of fatty amine acetates such as
the Acetamine series from Kao Corp.
[0267] These fatty amines can also be ethoxylated, such as Berol
380, 390, 453 and 455, the Ethomeens from Akzo Nobel or Marlazin
L10, OL2, OL20, T15/2, T50 from Condea Chemie.
[0268] The particles of the present invention can be introduced
into any pharmaceutical carrier for cosmetic, dermatological or
ophthalmic purposes. By way of example, mention will be made of
lotions, sera, gels and emulsions of all types.
[0269] The compositions according to the invention can be in any of
the pharmaceutical forms normally used for topical application, for
example in the form of solutions, gels, dispersions of the lotion
or serum type, emulsions which have a liquid or semi-liquid
consistency of the milk type, obtained by dispersion of a fatty
phase in an aqueous phase (O/W) or conversely (W/O), or suspensions
or emulsions which have a soft, semi-solid or solid consistency of
the cream or gel type, or else microemulsions, microcapsules,
microparticles or vesicular dispersions of ionic and/or nonionic
type. These compositions are prepared according to the usual
methods.
[0270] The compositions according to the invention can also
comprise any additive normally used in the cosmetics or
pharmaceutical field.
[0271] Of course, those skilled in the art will take care to select
this or these optional additional compound(s), and/or the amount
thereof, in such manner that the advantageous properties of the
composition according to the invention are not, or are not
substantially, impaired.
[0272] In particular, care will be taken to ensure that this
introduction does not harm the stability of the cationic particles
associated with the siRNA.
[0273] The compositions according to the invention may in
particular contain cosmetic or pharmaceutical active agents. This
will preferably involve depigmenting agents, sunscreens.
[0274] The depigmenting agents which can be incorporated into the
composition comprise, for example, the following compounds: kojic
acid; ellagic acid; arbutin and derivatives thereof such as those
described in EP-895,779 and EP-524,109; hydroquinone; aminophenol
derivatives such as those described in WO 99/10318 and WO 99/32077,
and in particular N-cholesteryloxycarbonyl-para-aminophenol and
N-ethyloxycarbonyl-para-aminophenol; iminophenol derivatives, in
particular those described in WO 99/22707;
L-2-oxothiazolidine-4-carboxylic acid or procysteine, and its salts
and esters; ascorbic acid and its derivatives, in particular
ascorbyl glucoside; and plant extracts, in particular extracts of
liquorice, mulberry and sculicap, without this list being
limiting.
[0275] The ultraviolet-radiation-screening agents can be selected
from organic UV-screening agents or inorganic
UV-radiation-screening agents.
[0276] The organic UV-screening agents in accordance with the
invention may be water-soluble, liposoluble or insoluble in the
usual cosmetic solvents. They are selected in particular from
anthranilates; cinnamic derivatives; dibenzoylmethane derivatives;
salicylic derivatives, camphor derivatives; triazine derivatives
such as those described in U.S. Pat. No. 4,367,390, EP-863,145,
EP-517,104, EP-570,838, EP-796,851, EP-775,698, EP-878,469 and
EP-933,376; benzophenone derivatives, in particular those described
in EP-1-046,391 and DE-10012408; .beta.,.beta.'-diphenyl acrylate
derivatives, benzotriazole derivatives, benzimidazole derivatives;
imadazolines; bisbenzoazolyl derivatives such as those described in
EP-669,323 and U.S. Pat. No. 2,463,264; p-aminobenzoic acid (PABA)
derivatives; methylenebis(hydroxyphenylbenzotriazole) derivatives
as described in U.S. Pat. Nos. 5,237,071, 5,166,355, GB 2303549, DE
19726184 and EP-893,119; screening polymers and screening silicones
such as those described in particular in WO 93/04665;
.alpha.-alkylstyrene-derived dimers such as those described in DE
19855649; and 4,4-diarylbutadiene derivatives such as those
described in EP-0-967,200 and DE 19755649.
[0277] The inorganic screening agents are generally pigments or
else nanopigments (average size of the primary particles: generally
from 5 nm and 100 nm, preferably from 10 nm and 50 nm) of metal
oxides which may or may not be coated, such as, for example,
nanopigments of titanium oxide (amorphous or crystalline in rutile
and/or anatase form), of iron oxide, of zinc oxide, of zirconium
oxide or of cerium oxide, which are all UV photoprotective agents
well known per se. Conventional coating agents are, moreover,
alumina and/or aluminium stearate. Such coated or uncoated metal
oxide nanopigments are in particular described in EP-0-518,772 and
EP-0-518,773.
[0278] The radiation-screening agents in accordance with the
invention are generally present in the compositions according to
the invention in proportions ranging from 0.1 to 20% by weight
relative to the total weight of the composition, and preferably
ranging from 0.2 to 15% by weight relative to the total weight of
the composition.
[0279] The present invention also features the administration of at
least one double-stranded RNA oligonucleotide of a sequence
selected from the group consisting of SEQ ID NOS. 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47 and 48 (Table I), for inhibiting
tyrosinase expression.
[0280] In particular, the oligonucleotides according to the
invention are useful as a bleaching agent and/or as an
anti-browning agent for the skin.
[0281] The double-stranded RNA oligonucleotides according to the
invention can also be used for the formulation of topical, cosmetic
or dermatological compositions suited to decrease melanin
synthesis, in particular with a view to treating hyperpigmentation,
and pigmentation marks and dyschromia, or for bleaching hair
follicles, regional hyperpigmentations due to melanocyte
hyperactivity, such as idiopathic melasmas, occurring during
pregnancy ("pregnancy mask" or chloasma) or oestro-progestin
contraception, localized hyperpigmentations due to benign
melanocyte hyperactivity and proliferation, such as senile
pigmentation marks referred to as actinic lentigo, accidental
hyperpigmentations, possibly due to post-lesional wound healing or
photosensitization, and also certain forms of leukoderma, such as
vitiligo. For the latter (the wound healing possibly resulting in a
scar that gives the skin a white appearance), since it is not
possible to repigment the lesioned skin, the process is completed
by depigmenting the areas of residual normal skin so as to impart
to the skin as a whole a homogeneous white tint.
[0282] The present invention also features a cosmetic method
(regime or regimen) for bleaching and/or lightening the complexion
and/or making the color of a browned skin uniform, comprising the
topical application of at least one double-stranded RNA
oligonucleotide of a sequence selected from the group consisting of
SEQ ID NOS. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48.
[0283] Preferably, the oligonucleotide is formulated in a topical
composition at a concentration of less than or equal to 1 nM.
[0284] More preferably, the oligonucleotide is associated with a
cationic particle less than or equal to 1 .mu.m in size, with a
zeta potential of from 10 to 80 mV, selected from among surfactant
micelles, block polymer micelles, liposomes of nonionic and
cationic surfactants, niosomes, oleosomes, particles of
nanoemulsions, nanocapsules, organic particles or inorganic
particles, as described above.
[0285] For the purposes of cosmetic, dermatological, ophthalmic or
pharmaceutical care, it is sought to avoid invasive methods such as
subcutaneous or ocular injections. The cationic particles
associated with siRNA according to the present invention can be
applied topically to the skin or the mucous membranes or in the
eye, in suspension or incorporated into an acceptable cosmocentric
carrier, such as lotions, sera, emulsified or non-emulsified gels,
oil/water, water/oil or multiple emulsions, microemulsions,
etc.
[0286] To promote the penetration of the particles associated with
siRNA, the water permeability may be modified; thus, it is possible
to control the water permeability by measuring the IWL (insensible
water loss) with a Tewameter TM210 or a Dermalab--Cortex
technology.
[0287] By way of example, the following methods may be used: [0288]
stripping (corneodisc, "varnish"), chemical peel or mechanical
dermabrasion before application of the compositions according to
the invention; [0289] pretreatment with a mixture of one or more
solvents having a defatting effect; [0290] cleansing the skin with
a detergent foaming product; [0291] occlusive pre- and/or
post-treatment either, for example, by covering the surface of the
skin to be treated with a watertight synthetic membrane (Blenderm,
for example), or by applying a layer of petroleum jelly. This has
the effect of blocking the natural IWL of the skin and causing
overhydration of the epidermal lipids which thus become more
permeable.
[0292] After application of the compositions of the present
invention, methods may be employed known to those skilled in the
art which promote the penetration of molecules into the skin, such
as, for example, iontophoresis or electroporation.
[0293] In the case of an in vitro skin model, the following
treatments may be carried out: [0294] before deposition of the
composition according to the invention, the Ca.sup.2+ content may
be reduced either by changing the medium (0.10-0.75 mM instead of
1.5 mM), or by adding a chelating agent. This has the effect of
decreasing intermembrane adhesion, thus increasing the permeability
of the skin (Effects of extra- and intracellular calcium
concentration on DNA replication, lateral growth, and
differentiation of human epidermal cells in culture. Virchows Arch
B Cell Pathol Incl Mol Pathol. 1990; 59(1): 17-25); [0295] using
iontophoresis, electroporation and any known methods for modifying
the permeability of the model.
[0296] In order to further illustrate the present invention and the
advantages thereof, the following specific examples are given, it
being understood that same are intended only as illustrative and in
nowise limitative. In said examples to follow, all parts and
percentages are given by weight, unless otherwise indicated.
EXAMPLE 1--Formulations
[0297] Cationic Micelles:
[0298] Exemplar 1: Octyl-p-glucoside/cetyltriammonium bromide at
the Molar Ratio of 5/1:
E1: 100 mM in distilled water
E2: 50 mM in distilled water
E3: 25 mM in distilled water
E4: 12.5 mM in distilled water.
[0299] The 2 surfactants (nonionic+cationic) are solubilized in
distilled water. A suspension of the siRNA of SEQ ID NO. 1 (20
.mu.M) is added at from 1:1 and 1:9 volume (siRNA: micelles), thus
reducing the micellar concentration in proportion.
[0300] Exemplar 2: Micelles of
decyl-.beta.-glucoside/behenyltriammonium chloride at the molar
ratio of 5/1 in distilled water. The same concentrations as in the
preceding exemplar are prepared.
[0301] These 2 suspensions can be applied to the skin for the
treatment of pigmentation marks and dyschromia or for the bleaching
of hair follicles.
[0302] Cationic liposomes:
[0303] Exemplar 1: "Fluid" Vesicles: TABLE-US-00001 PEG 400
isostearate 5.5% Behenyltriammonium chloride 0.5% Distilled water
qs 100
[0304] Exemplar 2: "Rigid" Vesicles: TABLE-US-00002 Sorbitan
palmitate 2.75% Cholesterol 2.75% Behenyltriammonium chloride 0.5%
Distilled water qs 100
[0305] These examples of liposome suspensions are realized by
dialysis. The lipids constituting the vesicles are solubilized in
an aqueous solution of octyl-.beta.-glucoside. This solution is
then dialyzed against water for 72 h.
[0306] The suspension of siRNA SEQ ID NO. 4 is then added, bringing
the concentration with respect to the vesicle to around 3% of
lipid. This suspension of nonionic liposomes can be applied to the
skin for the treatment of pigmentation marks and dyschromia or for
the bleaching of hair follicles.
[0307] Cationic Oleosomes:
[0308] Oil Phase: TABLE-US-00003 Sucrose mono-distearate marketed
by 0.45% Stearaineries Dubois Sorbitan stearate 4EO (Tween 61
Uniquema) 0.30% Behenyltriammonium chloride 0.21% Vit E acetate
0.5%: Jojoba oil 0.5% Stearyl heptanoate 1% Volatile silicone oil
1% Vit F glyceride 0.5% Preservative 0.02% BHT 0.01%
[0309] Aqueous Phase: TABLE-US-00004 Distilled water qs 100
Preservative 0.1%
[0310] This dispersion is obtained by high-pressure homogenization
in order to have a particle size of approximately 170 nm. A
suspension of siRNA SEQ ID NO. 16 (20 .mu.M) at ratios ranging from
1:1 to 1:20 (siRNA/oleosomes) is then added. The siRNA will then
complex with the surface of the particles.
[0311] Cationic Nanocapsules:
[0312] Organic Phase: TABLE-US-00005 Polycaprolactone (MW: 50 000)
1% Vit E 1% Dimethicone copolyol DC2 5695 (Dow Corning) 0.5%
Behenyltriammonium chloride 0.21% Acetone 200 ml
[0313] Aqueous Phase: TABLE-US-00006 Pluronic F68 0.5% Distilled
water 200 ml
[0314] The organic phase is introduced with stirring into the
aqueous phase. The acetone and 100 ml of aqueous phase are then
evaporated off so as to obtain the suspension of nanocapsules, the
size of which is 220 nm. A suspension of siRNA SEQ ID NO. 37 (20
.mu.M) at ratios ranging from 1:1 to 1:20 (siRNA/nanocapsules) is
then added. The siRNA will then complex with the surface of the
particles.
[0315] Organic Nanoparticles:
[0316] Organic Phase: TABLE-US-00007 Polyethylene adipate 2%
(Scientific Polymer products) Dimethicone copolyol DC2 5695 (Dow
Corning) 0.5% Behenyltriammonium chloride 0.21 % Acetone 200 ml
[0317] Aqueous Phase: TABLE-US-00008 Pluronic F68 0.5% Distilled
water 200 ml
[0318] The organic phase is introduced with stirring into the
aqueous phase. The acetone and 100 ml of aqueous phase are then
evaporated off so as to obtain the suspension of nanoparticles, the
size of which is 180 nm. A suspension of siRNA SEQ ID NO. 40 (20
.mu.M) at ratios ranging from 1:1 to 1:20 (siRNA/nanoparticles) is
then added. The siRNA will then complex with the surface of the
particles.
[0319] Cationic Nanoemulsions:
[0320] Oil Phase: TABLE-US-00009 PEG 400 isostearate marketed by
Uniqema 1% Behenyltriammonium chloride 1% Avocado oil 1% Jojoba oil
3% Cyclopentamethylsiloxane 2%
[0321] Aqueous Phase: TABLE-US-00010 Distilled water 30%
Dipropylene glycol 10%
[0322] Dilution Phase: TABLE-US-00011 Distilled water qs 100%
Preservative 0.1%
[0323] An emulsion is prepared by dispersing the oily phase in the
aqueous phase with very vigorous stirring. The suspension obtained
is then homogenized several times using a very-high-pressure
homogenizer, at a pressure of approximately 1200 b. The particle
size is of the order of 50 nm and the suspension is transparent.
The dilution phase is then added.
[0324] As in the previous cases, a suspension of siRNA SEQ ID NO.
42 (20 .mu.M) at ratios ranging from 1:1 to 1:20
(siRNA/nanoemulsion) is then added. The siRNA will then complex
with the surface of the particles.
EXAMPLE 2--Measurement of the Activity of the siRNAs According to
the Invention
[0325] The effectiveness of the 47 siRNAs of sequence SEQ ID NOS 1
to 47 according to the invention was evaluated in the
"pSCREEN-iT.TM. system" test developed by Invitrogen, set up to
evaluate the effectiveness on tyrosinase inhibition (GenBank
accession number M27160).
[0326] Experimental protocol for the test: [0327] 2.times.10.sup.4
A549 cells/well are seeded into a 48-well plate and cultured
overnight. [0328] Cotransfection is carried out in triplicate for 5
h using 2 .mu.g/ml of Lipofectamine 2000 (Invitrogen) complexed
with: [0329] tyrosinase pScreen-iT.TM. vector coupled to the LacZ
gene--10 ng/well [0330] luciferase reporter plasmid--20 ng/well
[0331] 1 nM Stealth.TM. RNA (sequences given in Table I) [0332] The
cells are lysed 24 h after the transfection and the
.beta.-galactosidase (.beta.-Gal) and luciferase (Luc) activities
are measured. The .beta.-Gal/Luc ratio determines the percentage
inhibition of tyrosinase.
[0333] The results obtained are reported in Table II.
TABLE-US-00012 TABLE II Assaying of the effectiveness of the 47
double-stranded RNA oligonucleotides on the degradation of
tyrosinase mRNA (GenBank accession number M27160). Oligonucteotide
% Oligonucleotide % (SEQ ID NO.) Inhibition (SEQ ID NO.) Inhibition
1 97.50% 22 77.91% 2 98.57% 23 97.29% 3 86.95% 24 90.50% 4 97.95%
25 95.17% 5 94.17% 26 90.60% 6 77.68% 27 87.11% 7 95.86% 28 91.58%
8 97.50% 29 96.00% 9 87.14% 30 90.39% 10 91.54% 31 10.38% 11 88.44%
32 97.93% 12 89.50% 33 84.79% 13 98.15% 34 64.43% 14 97.87% 35
97.71% 15 36.02% 36 92.12% 16 97.78% 37 97.07% 17 88.54% 38 9.55%
18 81.11% 39 90.22% 19 40.78% 40 97.44% 20 83.33% 41 88.11% 21
92.64% 42 98.71% 43 99.10% 46 98.64% 44 83.54% 47 94.14% 45
89.05%
[0334] Secondly, a dose-effect was determined on the 20 sequences
were most effective, i.e., with an effectiveness of greater than
91% at The results are reported in Table III. TABLE-US-00013 Table
III Assaying of the effectiveness of the 20 sequences selected, by
dose-effect with doses of 0.0016 nM to 1 nM. Oligonucleotide (SEQ
ID NO.) 1 nM 0.25 nM 0.063 nM 0.016 nM 1 97.37% 94.34% 89.47%
72.07% 2 97.98% 95.64% 89.34% 66.68% 4 97.93% 95.22% 90.24% 57.92%
5 91.33% 79.88% 61.47% 18.40% 7 96.86% 88.97% 76.45% 38.34% 8
97.84% 90.76% 81.12% 38.57% 13 98.13% 95.73% 91.11% 62.56% 14
97.59% 87.22% 68.77% 33.87% 16 97.95% 94.92% 83.40% 56.25% 23
96.05% 87.42% 62.32% 29.97% 25 93.45% 90.50% 78.36% 46.80% 29
96.42% 88.24% 70.64% 31.15% 32 96.88% 90.69% 80.33% 35.04% 35
97.42% 94.84% 88.34% 54.29% 37 96.38% 92.46% 88.24% 53.92% 40
97.65% 95.08% 91.59% 60.64% 42 98.25% 96.54% 92.58% 53.46% 43
98.46% 95.60% 89.21% 38.85% 46 98.77% 94.81% 84.23% 48.74% 47
94.60% 76.71% 52.94% 30.18%
[0335] The siRNAs according to the present invention show an
effectiveness of greater than 94% at 1 nM for the 20 sequences most
effective. The lowest dose tested is 0.016 nM for an effectiveness
of 72% on degradation of the mRNA encoding tyrosinase.
EXAMPLE 3--Evaluation of a Possible Interferon-Type Response Caused
by the siRNAs According to the Invention
[0336] It was verified that the siRNAs which are subjects of the
present invention did not induce an interferon-type response. For
this, the expression of the OAS-1 and IFIT-1 (interferon-inducible
tetratricopeptide repeat domain) genes, known to be induced by
interferon (Wieland S F et al., Searching for Interferon-induced
Genes That Inhibit Hepatitis B Virus Replication in Transgenic
Mouse Hepatocytes, J. of Virology 2003; 77: 1227-1236. Persengiev S
P et al., Nonspecific, concentration-dependent stimulation and
repression of mammalian gene expression by small interfering RNAs
(siRNAs). RNA 2004; 10: 12-18. Bridge A J et al., Induction of an
interferon response by RNAi vectors in mammalian cells. Nature
Genet. 2003; 34: 263-264. Scacheri P C et al., Short interfering
RNAs can induce unexpected and divergent changes in the levels of
untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA
2004,101: 1892-1897. Sledz C A et al., Activation of the interferon
system by short-interfering RNAs. Nat Cell Biol. 2003; 9: 834-9.
Patzwahl R et al., Enhanced expression of interferon-regulated
genes in the liver of patients with chronic hepatitis C virus
infection: detection by suppression-subtractive hybridization. J.
Virol. 2001; 75: 1332-1338.), was measured by quantitative PCR
(qPCR) according to the protocol described in the "BLOCK-iT.TM.
RNAi Stress Response Control Kit (Human) for monitoring
interferon-mediated stress response to double-stranded RNA in human
cells" marketed by Invitrogen.
[0337] Measurement of the Level of Expression of the hOAS-1
Gene:
[0338] The level of expression of the hOAS-1 gene was related to
that of the GAPDH reference gene. TABLE-US-00014 hOAS-1/ Sample
GAPDH Stdev dsRNA of SEQ ID NO. 1 - 1 nM 0.608 0.046 dsRNA of SEQ
ID NO. 2 - 1 nM 0.668 0.292 dsRNA of SEQ ID NO. 4 - 1 nM 0.608
0.070 dsRNA of SEQ ID NO. 13 - 1 nM 1.232 0.866 dsRNA of SEQ ID NO.
46 - 1 nM 0.911 0.221 dsRNA of SEQ ID NO. 1 - 50 nM 1.080 0.500
Control sequence at 1 nM 2.141 1.336 Positive control (long dsRNA
of 1 kb) 24.905 6.431 dsRNA of SEQ ID NO. 1 - 0.1 nM 0.856 0.534
dsRNA of SEQ ID NO. 2 - 0.1 nM 0.866 0.300 dsRNA of SEQ ID NO. 4 -
0.1 nM 0.966 0.568 dsRNA of SEQ ID NO. 13 - 0.1 nM 1.238 0.451
dsRNA of SEQ ID NO. 46 - 0.1 nM 1.262 0.328 Control sequence at 50
nM 0.807 0.404 Control sequence at 0.1 nM 1.949 1.502
[0339] Result: Only the positive control (long dsRNA of 1 kb)
induces a significant increase in hOAS-1 gene expression. The
sequences tested (SEQ ID NOS. 1, 2,4,13 and 46) do not
significantly increase hOAS-1 gene expression.
[0340] Measurement of the Level of Expression of the hIFIT-1 Gene:
TABLE-US-00015 Threshold Sample cycle Stdev dsRNA of SEQ ID NO. 1 -
1 nM 36.15 0.20 dsRNA of SEQ ID NO. 2 - 1 nM 32.77 1.85 dsRNA of
SEQ ID NO. 4 - 1 nM 35.98 0.88 dsRNA of SEQ ID NO. 13 -1 nM 35.41
1.88 dsRNA of SEQ ID NO. 46 - 1 nM 34.42 3.24 dsRNA of SEQ ID NO. 1
- 50 nM 34.16 3.02 Control sequence at 1 nM 31.30 1.98 Positive
control (long dsRNA of 1 kb) 25.70 0.79 dsRNA of SEQ ID NO. 1 - 0.1
nM 32.47 3.07 dsRNA of SEQ ID NO. 2 - 0.1 nM 35.38 1.41 dsRNA of
SEQ ID NO. 4 - 0.1 nM 34.86 1.86 dsRNA of SEQ ID NO. 13 - 0.1 nM
33.22 2.33 dsRNA of SEQ ID NO. 46 - 0.1 nM 33.89 2.03 Control
sequence at 50 nM 35.70 3.30 Control sequence at 0.1 nM 33.65
3.90
[0341] Result: Only the positive control (long dsRNA of 1 kb)
induces a significant expression of the hIFIT-1 gene detected at a
threshold cycle value of approximately 25. The sequences tested
(SEQ ID NOS. 1, 2, 4, 13 and 46) induce hIFIT-1 gene expression
only for threshold cycle values of approximately 32-36, i.e., a
difference of 7-11 cycles corresponding to an amount of messengers
which is 102-103 times lower.
[0342] These assays make it possible to conclude that the dsRNAs
according to the invention do not induce an interferon-type
response.
[0343] Each patent, patent application, publication, text and
literature article/report cited or indicated herein is hereby
expressly incorporated by reference.
[0344] While the invention has been described in terms of various
specific and preferred embodiments, the skilled artisan will
appreciate that various modifications, substitutions, omissions,
and changes may be made without departing from the spirit thereof.
Accordingly, it is intended that the scope of the present invention
be limited solely by the scope of the following claims, including
equivalents thereof.
Sequence CWU 1
1
48 1 25 RNA Homo sapiens 1 gcguaauccu ggaaaccaug acaaa 25 2 25 RNA
Homo sapiens 2 gccuaccuca cuuuagcaaa gcaua 25 3 25 RNA Homo sapiens
3 ccugugucuc cucuaagaac cugau 25 4 25 RNA Homo sapiens 4 ccauagggac
cuauggccaa augaa 25 5 25 RNA Homo sapiens 5 ccgauuggag gaguacaaca
gccau 25 6 25 RNA Homo sapiens 6 ggaccuuuac ggcguaaucc uggaa 25 7
25 RNA Homo sapiens 7 ggcguaaucc uggaaaccau gacaa 25 8 25 RNA Homo
sapiens 8 ccugucagaa uauccuucug uccaa 25 9 25 RNA Homo sapiens 9
ccuggaaacc augacaaauc cagaa 25 10 25 RNA Homo sapiens 10 ccaauaugaa
ucugguucca uggau 25 11 25 RNA Homo sapiens 11 gguuccaugg auaaagcugc
caauu 25 12 25 RNA Homo sapiens 12 gcaaagcaua ccaucagcuc agacu 25
13 25 RNA Homo sapiens 13 ggaguacaac agccaucagu cuuua 25 14 25 RNA
Homo sapiens 14 gcagagguuc cugucagaau auccu 25 15 25 RNA Homo
sapiens 15 gcagauuguc uguagccgau uggag 25 16 25 RNA Homo sapiens 16
gaucaacacc cauguuuaac gacau 25 17 25 RNA Homo sapiens 17 gaguacaaca
gccaucaguc uuuau 25 18 25 RNA Homo sapiens 18 gcauuauuau gugucaaugg
augca 25 19 25 RNA Homo sapiens 19 gaccuuuacg gcguaauccu ggaaa 25
20 25 RNA Homo sapiens 20 gccuuggcau agacucuucu uguug 25 21 25 RNA
Homo sapiens 21 gcacagauga guacauggga gguca 25 22 25 RNA Homo
sapiens 22 gagagacgac ucuuggugag aagaa 25 23 25 RNA Homo sapiens 23
gaggaguaca acagccauca gucuu 25 24 25 RNA Homo sapiens 24 ucuguagccg
auuggaggag uacaa 25 25 25 RNA Homo sapiens 25 ucccuagagc cugugucucc
ucuaa 25 26 25 RNA Homo sapiens 26 ucuuggcaga uugucuguag ccgau 25
27 25 RNA Homo sapiens 27 ucuuguugcg gugggaacaa gaaau 25 28 25 RNA
Homo sapiens 28 gccaucaguc uuuaugcaau ggaac 25 29 25 RNA Homo
sapiens 29 ccaaacugca cagagagacg acucu 25 30 25 RNA Homo sapiens 30
ccugaguuug acccaauaug aaucu 25 31 25 RNA Homo sapiens 31 ccaauuagcc
aguuccugca gaccu 25 32 25 RNA Homo sapiens 32 ggaggaguac aacagccauc
agucu 25 33 25 RNA Homo sapiens 33 ccauggauaa agcugccaau uucag 25
34 25 RNA Homo sapiens 34 acucuucuug uugcgguggg aacaa 25 35 25 RNA
Homo sapiens 35 acaacagcca ucagucuuua ugcaa 25 36 25 RNA Homo
sapiens 36 accucacuuu agcaaagcau accau 25 37 25 RNA Homo sapiens 37
gucuggaugc auuauuaugu gucaa 25 38 25 RNA Homo sapiens 38 accuugugag
gacuagagga agaau 25 39 25 RNA Homo sapiens 39 guuccaugga uaaagcugcc
aauuu 25 40 25 RNA Homo sapiens 40 acagagagac gacucuuggu gagaa 25
41 25 RNA Homo sapiens 41 gccugugucu ccucuaagaa ccuga 25 42 25 RNA
Homo sapiens 42 ucaggcagag guuccuguca gaaua 25 43 25 RNA Homo
sapiens 43 caacagccau cagucuuuau gcaau 25 44 25 RNA Homo sapiens 44
gcauaccauc agcucagacu auguc 25 45 25 RNA Homo sapiens 45 ccaucagucu
uuaugcaaug gaacg 25 46 25 RNA Homo sapiens 46 ggaucaacac ccauguuuaa
cgaca 25 47 25 RNA Homo sapiens 47 cagagguucc ugucagaaua uccuu 25
48 19 RNA Homo sapiens 48 ugcaccacuu gggccucaa 19
* * * * *